Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

New England Journal of Medicine

Volumn 355, Issue 17, 2006, Pages 1772-1779

  Ahmed, A Razzaque ^a,b   Spigelman, Zachary ^a,c   Cavacini, Lisa A ^d   Posner, Marshall R ^c,d  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; MEMBRANE ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THALIDOMIDE;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BODY SURFACE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEVER; HUMAN; INFECTION; NAUSEA; PEMPHIGUS VULGARIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECURRENT DISEASE; RIGOR; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; DESMOGLEINS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KERATINOCYTES; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PEMPHIGUS; RECURRENCE; REMISSION INDUCTION;

EID: 33750291236     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062930     Document Type: Article

References (39)

1. Pemphigus: current concepts. Ann Intern Med 1980;92:396-405.
2. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994;189:Suppl 1:85-9.
3. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 1995;92:5239-43.
4. Hacker MK, Janson M, Fairley JA, Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol 2002;105:64-74.
5. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol 1996;132:203-12.
6. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005;6:327-42.
7. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375-91.
8. Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs 2004;13:1019-32.
9. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.
10. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705-10.
11. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503.
12. Yeh SW, Cavacini LA, Bhol KC, et al. Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol 2006;120:68-75.
13. Cavacini LA, Emes CL, Power J, Duval M, Posner MR. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J Immunol 1994;152:2538-45.
14. Lehrnbecher T. Intravenous immunoglobulins in the prevention of infection in children with hematologic-oncologic diseases. Klin Padiatr 2001;213:Suppl 1:A103-A105. (In German.)
15. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:117-30.
16. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-12.
17. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 2005;1051:743-78.
18. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620-5.
19. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003;28:366-8.
20. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91-6.
21. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004;50:974-6.
22. Kong HH, Prose NS, Ware RE, Hall RP III. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005;22:461-4.
23. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004;51:817-9.
24. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002;47:785-8.
25. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005;153:449-51.
26. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases - successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003;88:ELT24.
27. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.
28. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
29. Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005;8:193-205.
30. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005;90:1273-4.
31. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
32. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
33. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-7.
34. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
35. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3.
36. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005;19:423-6.
37. Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:2252-4.
38. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
39. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.